Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors.

Macromolecule Content

• Total Structure Weight: 53.76 kDa 
• Atom Count: 3633 
• Residue Count: 412 
• Unique protein chains: 1

4NH7

Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity

• DOI: 10.2210/pdb4NH7/pdb

• Classification: CHAPERONE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2013-11-04 Released: 2014-01-15 
• Deposition Author(s): Zuccola, H.J., Ernst, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.243 
• R-Value Work: 0.206 
• R-Value Observed: 0.208 

Literature

Correlation between chemotype-dependent binding conformations of HSP90 alpha / beta and isoform selectivity-Implications for the structure-based design of HSP90 alpha / beta selective inhibitors for treating neurodegenerative diseases.

Ernst, J.T., Liu, M., Zuccola, H., Neubert, T., Beaumont, K., Turnbull, A., Kallel, A., Vought, B., Stamos, D.

(2014) Bioorg Med Chem Lett 24: 204-208

• PubMed: 24332488 
• DOI: 10.1016/j.bmcl.2013.11.036
• Structures With Same Primary Citation


• PubMed Abstract: 
  

HSP90 continues to be a target of interest for neurodegeneration indications. Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro. Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity. The rational design of HSP90α/β inhibitors selective versus the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities. Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.

---

Organizational Affiliation: 

Vertex Pharmaceuticals, Department of Chemistry and Drug Innovation, 11010 Torreyana Road, San Diego, CA 92121, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Heat shock protein HSP 90-alpha	A, B	233	Homo sapiens	Mutation(s): 0  Gene Names: HSP90AA1, HSP90A, HSPC1, HSPCA
Find proteins for P07900 (Homo sapiens) Explore P07900  Go to UniProtKB:  P07900
NIH Common Fund Data Resources
PHAROS  P07900 GTEx  ENSG00000080824

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
E0G	A, B	4-[6,6-dimethyl-4-oxidanylidene-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-oxidanylcyclohexyl)amino]benzamide C23 H27 F3 N4 O3 ZFVRYNYOPQZKDG-MQMHXKEQSA-N
GOL	A, B	GLYCEROL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
HIE	Ki:  4   nM  Binding MOAD

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.243 
• R-Value Work: 0.206 
• R-Value Observed: 0.208 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 114.98	α = 90
b = 88.04	β = 124.53
c = 71.07	γ = 90

Software Package:

Software Name	Purpose
PROCESS	data collection
BUSTER	refinement
PROCESS	data reduction
PROCESS	data scaling
BUSTER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-11-04 
• Released Date: 2014-01-15 
Deposition Author(s): Zuccola, H.J., Ernst, J.

Revision History 

• Version 1.0: 2014-01-15
  Type: Initial release
  
• Version 2.0: 2017-11-29
  Changes: Atomic model, Database references, Derived calculations, Non-polymer description, Source and taxonomy, Structure summary